Innovative Antimicrobial Technologies

Transcription

1 A New Level of Respiratory Protection PJ Messier, CEO Triosyn Corp. For Official Use Only Innovative Antimicrobial Technologies 1

2 TRIOSYN CORP. AT A GLANCE Triosyn Corp. is dedicated to the fight against microbial threats through scientific development and commercial distribution of innovative Triosyn-based antimicrobial products Mission Our Specialty R&D Triosyn Technology Products Lead the fight against microbial threats Development of high-performance antimicrobial products World-class research facilities & scientists Triosyn resin (proprietary) 88 patents issued and/or pending Superior antimicrobial products designed for maximum protection 2

3 TRIOSYN AIR FILTRATION TECHNOLOGY Trap Technology Today s air purification systems: conventional air filtration Insufficient against airborne viruses Viral Penetration AIR FLOW Conventional Air Filtration Trap and Kill Technology Triosyn Antimicrobial Filtration Combination of antimicrobial with filtration membrane Kills viruses penetrating the membrane AIR FLOW 3

4 TRIOSYN TECHNOLOGY Broad-spectrum interactive antimicrobial polymer Efficacy greater than % against viruses, bacteria, spores, protozoa, algae and fungi No negative toxicology impact to humans Versatile - equally effective in air, fluid, surface and dermatological applications No microbial resistance demonstrated All claims validated by third-party testing 4

5 Micro-Biological Performance Microoganisms tested against Triosyn Products Viruses Bacteria Sporulating Bacteria Fungi Protozoa Фx174 Coliphage Human Immuno. Virus (HIV) MS2 Coliphage Newcastle Disease Virus Poliovirus Type 1 Rotavirus SA-11 SARS coronavirus Brucella abortus Enterobacter aerogenes Enterococcus faecalis Erwinia herbicola Francisella tularensis Klebsiella pneumoniae Klebsiella terrigena Legionella sp. Micrococcus luteus Drug-Res. Staphy. aureus (MRSA) Proteus mirabilis Pseudomonas aeruginosa Pseudomonas pseudomallei Salmonella sp. Serratia marcescens Shigella flexneri Staphylococcus aureus Staphylococcus epidermidis Bacillus anthracis Bacillus atrophaeus (BG) Bacillus subtilis Aureobasidium pullulans Aspergillus niger Candida albicans Cladosporium herbarum Penicillium citrinum Penicillium sp. Rhodotorula rubra Trichophyton mentagrophytes Cryptosporidium parvum Giardia lamblia Giardia muris Microoganisms tested against Triosyn Air Filtration or Antimicrobial Finishes Viruses Bacteria Sporulating Bacteria Fungi Фx174 Coliphage MS2 Coliphage Newcastle Disease Virus SARS coronavirus Avian & Human Influenza Erwinia herbicola Escherichia coli Klebsiella pneumoniae Klebsiella terrigena Micrococcus luteus Staphylococcus aureus Staphylococcus epidermidis Bacillus atrophaeus (BG) Bacillus subtilis Aspergillus niger Candida albicans Cladosporium herbarum Rhodotorula rubra Trichophyton mentagrophytes 5

6 Minimum Infectious Doses Airborne Viral Pathogen Size in Microns Associated Diseases Infectious Dose Ref. Numbers Adenovirus Respiratory infections, tumors HID50: 0.5 TCID 50 1, 3, 6, 7 Dengue, Ebola & Marburg viruses; Hantavirus; Lassa & Yellow fever viruses Viral hemorrhagic fevers (VHFs) MID: 1-10 PFU 2, 4, 8 Eastern, Western & Venezuelan Equine Encephalomyelitis (EEE, WEE & VEE) viruses Viral encephalitis MID: PFU 2, 8 Influenza A2 Bethesda (H2N2) virus Influenza *HID50: 3.0 TCID 50 6, 7 Variola virus Smallpox *MID: PFU 2, 5, 8 *Estimated References Couch R.B. et al Effect of Route of Inoculation on Experimental Respiratory Viral Disease in Volunteers and Evidence for Airborne Transmission. Bacteriol. Rev., Vol. 30(3), pp Franz D.R. et al Clinical Recognition and Management of Patients Exposed to Biological Warfare Agents. JAMA, Vol. 278(5), pp Hamory B.H., Couch R.B., Douglas G.R. Jr., Black S.H. and Knight V Characterization of the Infectious Unit for Man of Two Respiratory Viruses. Proc. Soc. Exp. Biol. Med., Vol. 139(3), pp Health Canada, Office of Laboratory Security, MSDS Index, Online: Hogan C.J., Harchelroad F CBRNE Smallpox, emedicine Journal, Vol. 2(10), 15 pp. Knight V Viruses as Agents of Airborne Contagion. Ann. N.Y. Acad. Sci., Vol. 353, pp Knight V., Gilbert B.E., Wilson S.Z Airborne Transmission of Virus Infections. in Banbury Report 22: Genetically Altered Viruses and the Environment, Vol. 22, B. Fields, M.A. Martin and D. Kamely, eds Cold Spring Harbor, pp USAMRIID Blue Book (USAMRIID s Medical Management of Biological Casualties Handbook), 5th edition, August Online: 6

7 Viral Filtration Efficiency of Respirators MS2 coliphage Penetration Levels through Triosyn T-3000 and Commercial N95 Respirators tested at 85 LPM 1,E+08 Penetration (PFU/m 3 of air) 1,E+07 1,E+06 1,E+05 1,E+04 1,E+03 1,E+02 1,E+01 Challenge N95 A N95 B T-3000 (n=4) 1,E Detection Limit = PFU/m 3 Source: Department of Defense (DoD) independent testing Ref: Challenge Concentration: CAMR (UK), TNO (NL), UNLV (USA) Time (h) 7

8 Viral Filtration Efficiency of Respirators Comparison of MS2 coliphage Penetration Levels through Triosyn T-3000 and Commercial N95 Respirators against Low Viral Challenge Concentrations over 90 minutes Filtration Periods tested at 85 LPM 1,E+04 Penetration (PFU/m 3 of air) 1,E+03 1,E+02 1,E+01 T-3000 N95 A N95 B DL 1,E+00 1,E+03 1,E+04 1,E+05 1,E+06 Detection Limit = PFU/m 3 Challenge size (PFU/m 3 of air) Source: Triosyn Research, Inc. R&D Division of Triosyn Corp. Ref: Challenge Concentration Source: Beggs C.B. (2003), Kowalski and Bahnfleth (1998). 8

9 Viral Filtration Efficiency of Respirators Longevity Study - MS2 coliphage Penetration Levels through Triosyn T-3000 and Commercial N95 Respirators tested at 85 LPM Viral Penetration (PFU/m3) 1,00E+05 1,00E+04 1,00E+03 1,00E+02 1,00E+01 1,00E+00 C+ T3000 C+ N95 T3000 (n=3) N95 A N95 B 1,00E DL Detection Limit = PFU/m 3 Sampling time (h) Source: Triosyn Research, Inc. R&D Division of Triosyn Corp. Ref: Challenge Concentration Source: Beggs C.B. (2003), Kowalski and Bahnfleth (1998). 9

10 Sterilization Reusability: Sterilization of N95 and Triosyn T-3000 Facemasks Down Selected Sterilization Method: Ethylene Oxide Facemask Integrity: Maintained Microbial Efficiency: Maintained Particulate Filtration Efficiency: Maintained Toxicology Impact: None, Note: post ETO treatment minimum of 16 hours required before reusing facemask 10

11 Annex 11

12 Toxicology Toxicological Performance of Triosyn T-3000 Respirator (n=4) Flow: 85 LPM Duration: 8 hours Time point (min) Conc. Iodine (mg/m3) 15 BDL 30 BDL 45 BDL 60 BDL 75 BDL 90 BDL 105 BDL 120 BDL 135 BDL 150 BDL 165 BDL 180 BDL 195 BDL 210 BDL 220 BDL 225 BDL 240 BDL 255 BDL 270 BDL 285 BDL 300 BDL 315 BDL 330 BDL 345 BDL 360 BDL 375 BDL 390 BDL 405 BDL 420 BDL 435 BDL 450 BDL 465 BDL 480 BDL Sum of Dietary Intake = 0.071mg Threshold Limit Value (OSHA) = 1.036mg/m 3 Recommended Dietary Allowance for an Adult = 1.1mg/day Below Detection Limit (BDL) = 1.10E-02 mg/m 3 Toxicological Performance T-3000 P95 Respirator Triosyn Polymer Studies Results Primary Dermal Irritation Non Irritant Oral Irritation Non Irritant Acute Oral Toxicity LD>5000 mg/kg Acute Inhalation Toxicity LC 50 >2.21 mg/l Acute Dermal Toxicity LD>5000 mg/kg Primary Eye Irritation Mild Irritant Dermal Sensitization Non Sensitizer Gene Mutation Non Mutagenic Mammalian Erythrocyte Micronucleus Non Mutagenic Chromosome Aberration Non Clastogenic 12

13 Viral Filtration Efficiency of Respirators Viral Filtration Efficiency of Triosyn T-3000 and Commercial N99 Respirators Viral Filtration Efficiency (%) 100,0% 99,8% 99,6% 99,4% 99,2% 99,0% 98,8% 98,6% 98,4% T-3000 (n=6) N99 (n=6) Time (h) Flow Rate: 85.0 LPM Virus: MS2 (as per Scientific Literature Protocols) Source: International Laboratories 13

14 Viral Filtration Efficiency of Respirators Viral Filtration Efficiency of Triosyn T-3000 and Commercial FFP3 Respirators Viral Filtration Efficiency (%) 100,0% 99,9% 99,8% 99,7% 99,6% 99,5% 99,4% 99,3% 99,2% 99,1% 99,0% Time (h) T-3000 (n=6) FFP3 (n=3) Flow Rate: 85.0 LPM Virus: MS2 (as per Scientific Literature Protocols) Source: International Laboratories 14

15 Viral Filtration Efficiency of Respirators Viral Filtration Efficiency of Triosyn T-3000 and Commercial FFP2 Respirators Viral Filtration Efficiency (%) 100,0% 99,9% 99,8% 99,7% 99,6% 99,5% 99,4% 99,3% 99,2% 99,1% 99,0% Time (h) T-3000 (n=6) FFP2 (n=3) Flow Rate: 85.0 LPM Virus: MS2 (as per Scientific Literature Protocols) Source: International Laboratories 15